Drugs / Restylane-L®
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04169308 | Jan 2019 → Jul 2020 | nose, anomalous shape of | DeNova Research | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03460158 | Aug 2020 → Feb 2024 | — | University of Pennsylvania | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03313934 Background | Nov 2017 → Nov 2018 | — | Rejuva Medical Aesthetics | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Restylane-L | “The use of Restylane-L to volumize the tear trough has been well documented.” NCT03313934 ↗ |
| Modality | Other / unclassified | “using HA fillers: Restylane-L in nasolabial folds and marionette lines” PMID 40178806 ↗ Apr 2025 |
| Route | Other | “dermal implantation” NCT03460158 ↗ |